Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study.

Key Points

• This research aims to compare the effects of sodium-glucose co-transporter 2 inhibitors and DPP-4 inhibitors on cancer rates among individuals with type 2 diabetes.
• Conducted a large real-world observational study
• Compared cancer rates between SGLT-2i and DPP-4i users
• Analyzed rates of obesity-associated cancers and all-cancer outcomes
• No significant difference in obesity-associated cancer rates between SGLT-2i and DPP-4i users
• SGLT-2i users had a modestly lower overall cancer rate
• Clinical significance of findings remains uncertain